Researchers are engaged in exploring CRISPR technology application in performing microsurgery on genes. Most of the conventional gene therapies coarsely place new genetic material at a random location in the cell, and can only add a gene. In contrast, CRISPR and the other new tools also give scientists a more precise way to delete and edit specific bits of DNA, even by changing a single base pair.

Although innovative programmable editing tools, such as zinc finger nucleases and transcription activator-like effector nucleases have significantly improved the efficiency for precise genome modification, these techniques have limitations. CRISPR (Clustered Regularly Interspaced Short Pallindromic Repeats)/Cas9 technology represents a significant improvement over these other next-generation genome editing tools, reaching a new level of targeting, efficiency, and ease of access. The CRISPR/Cas9 system allows for site-specific genomic targeting in virtually any organism.

Research also showed that CRISPR can target multiple genes in a cell at one time. CRISPR-Cas9 is still very much restricted to research laboratories, but due to rapid advancements in this technology, CRISPR/Cas9 market is likely to experience a remarkable growth in the future. Owing to these factors the market for this targeted genome editing approach is expected to grow at a high double digit CAGR during 2016-2022.

According to a new research report by RNCOS entitled, “Global CRISPR/Cas9 Market Outlook 2022”, CRISPR/Cas9 technology has revolutionized genome editing, allowing a previously unattainable level of genomic targeting, efficiency and simplicity. Further adding to the applications of the CRISPR/Cas9, CRISPR has its applications in genome editing or genetic engineering, gRNA database, CRISPR plasmid preparation, human stem cells, genetically modified organisms or crops, and cell line engineering. Moreover, the simplicity and robustness of the CRISPR/Cas9 technology will make it possible to respond to newly emerging strains by deploying appropriate sgRNA transgenes into a crop.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM864.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.